English

Interim report Q3, 2023: Profitable growth globally despite headwind in the U.S.

Report this content

Third quarter

  • Sales of SEK 848 (798) million, an increase of 6%, or 7% excluding discontinued business. In local currencies the growth was 2% and excluding discontinued business 3%.
  • Sales, in local currencies and excluding discontinued business, increased by 5% in APAC and 14% in EMEA, while Americas decreased by 8%.
  • Sales, in local currencies and excluding discontinued business, increased by 8% in Consumables and 14% in Technologies, while Genetic Services decreased by 5%.
  • Gross margin increased to 55.7% (53.6).
  • Operating income before depreciation and amortisation (EBITDA) was SEK 287 (276) million, giving an EBITDA margin of 33.9% (34.5). The EBITDA is stronger given the non-recurring income for the quarter last year.
  • Operating cash flow increased to SEK 214 million (200).
  • Net income increased to SEK 122 (108) million, resulting in earnings per share of SEK 0.90 (0.80).
     

First nine months

  • Sales of SEK 2,607 (2,379) million, an increase of 10%, or 11% excluding discontinued business. In local currencies, growth was 4% and excluding discontinued business 5%.
  • Sales, in local currencies and excluding discontinued business, increased by 15% in APAC and 6% in EMEA, while Americas decreased by 3%.
  • Sales, in local currencies and excluding discontinued business, increased by 12% in Consumables and 4% in Technologies, while Genetic Services decreased by 1%.
  • Gross margin increased to 56.1% (55.3).
  • Operating income before depreciation and amortisation (EBITDA) was SEK 842 (777) million. Adjusted for non-recurring costs, EBITDA was SEK 868 (777) million, giving an EBITDA margin of 33.3% (32.6).
  • Operating cash flow increased to SEK 586 million (470).
  • Net income increased SEK 328 (321) million, resulting in earnings per share of SEK 2.42 (2.36).

Gothenburg, October 27, 2023
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 27-10-2023 08:00 CET.

Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_____________________________________________________________________________________________________________________________________________________________

Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient’s fertility treatment. Currently, we are approximately 1,100 people worldwide, headquartered in Gothenburg, Sweden. 

Vitrolife Group’s products and services are available in more than 125 countries, through our own presence in more than 25 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a healthy baby. The Vitrolife AB (publ) share is listed on the Nasdaq Stockholm.
_____________________________________________________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. Fax: +46 31 721 80 99.
E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.

Subscribe

Documents & Links